CTOs on the Move

Aerovate Therapeutics

www.aerovatetx.com

 
Aerovate Therapeutics is a biotechnology company focused on developing drugs for rare cardiopulmonary disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Aerovate Therapeutics raised $72.6M on 08/06/2020

Similar Companies

Fulgent Genetics

Fulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent Genetics` proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Combining next generation sequencing, or NGS, with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of the Company`s business is its ability to provide expansive options and flexibility for all clients` unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated laboratory services.

Oncoceutics Pharmaceuticals Inc

Oncoceutics Pharmaceuticals Inc is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aktis Oncology

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.

Barc USA

Barc USA is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rapid Pathogen Screening

Founded in 2004, Rapid Pathogen Screening is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to rapidly identify patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being used to develop tests for bio-terrorism and chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment.